Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHW1LI)

Drug Name

Iptakalim Drug Info

Synonyms

2,3-Dimethyl-N-isopropyl-2-butanamine hydrochloride

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Potassium channel unspecific (KC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nateglinide	DMLK2QH	Diabetic complication	5A2Y	Approved	[2]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[2]
Dronedarone	DMA8FS5	Angina pectoris	BA40	Approved	[3]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[2]
Amifampridine	DMK08L3	LambertEaton myasthenic syndrome	8C62	Approved	[4]
Minoxidil	DMA2Z4F	Alopecia	ED70	Approved	[2]
Pinacidil	DMRADYL	High blood pressure	BA00	Approved	[2]
Dalfampridine	DMM0PDO	Multiple sclerosis	8A40	Approved	[5]
Ibutilide	DMKXY2R	Atrial fibrillation	BC81.3	Approved	[2]
Diazoxide	DML1538	Congenital hyperinsulinism	5A4Y	Approved	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Potassium channel unspecific (KC)	TT1VOHK	NOUNIPROTAC	Opener	[1]

------------------------------------------------------------------------------------

References

1	Iptakalim: A novel multi-utility potassium channel opener. J Pharmacol Pharmacother. 2012 Jan;3(1):12-4.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
4	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
5	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.